Vectura Share Discussion Threads

[boadicea] 13/2/2018 20:58

This has some of the signs of a price being engineered down prior to a 'generous' bid - i.e. generous in comparison to the immediate pre-bid price. In the present case this could be 110 - 120p or about half what it ought to be.

[semper vigilans] 13/2/2018 17:53

I would hate to calculate how much cash they have wasted on the buybacks bearing in mind the current price.

[pooroldboy55] 13/2/2018 16:37

And yet again UT price well below bid not looking good again for tomorrow! !!!!

[a1ord53] 13/2/2018 16:32

IMO CEO and CFO should go - its disaster what they did merging and ruining SKP and VEC .

Company worth atleast 1 bil £ valuation - 1.3-1.5 £ a share and we are at multi years low .
Why major shareholders like Woodford - tolerate this situation ?

After spent all money buying back from short sellers , now company even in much worse position , cause no more support for share price and short sellers will kill share price completely in order to cover their shorts.

[pooroldboy55] 13/2/2018 16:11

Now at 6 year low still think going into 60s something very wrong somewhere and still nothing from BOD. A an where would the price be without buy back?

[jopper74] 13/2/2018 16:05

Desperately need some good news......and fast to stop this sinking even further!

[pooroldboy55] 12/2/2018 10:28

Here's hoping but can see this going into the 60s no support anywhere.

[diesel] 12/2/2018 10:22

Not so sure, volume seems lower, think 80 is support for now.

[pooroldboy55] 12/2/2018 10:17

Looks like back to the normal down trend today.Friday just a flash in the pan?.

[diesel] 10/2/2018 10:27

POB , this dead cat has lost all its bounce!
This time last year the share price was going from 130-160p, I sold some at 140 and felt gutted to see it go to 160, funny old game!

[pooroldboy55] 10/2/2018 08:58

Well got that one wrong big time. BLUE !!!!!!!!!!

[alexchry] 09/2/2018 11:55

a1ord53-I do not think the fall in share price is entirely due to the delay in the approval of Advair generic. It has been a long time since any good news came out of Vec and there has been plenty of disappointing news such as the slowdown in Flutiform sales. The change of tack by the management has made the company more boring but more financially secure, perhaps that is not what investors were looking for.

[pooroldboy55] 09/2/2018 11:47

Well i don't think it will be Hikma.
Ps soon midday so sell off should start before long.

[a1ord53] 09/2/2018 11:44

Vectura lost half a billion £ in capitalisation.
According research on this board Generic Advair doesnt worth half a billion £.
So obviously city just in control of share price and keep selling in every bounce.
Management is impotent in terms improving share price and without fresh money will be continueing impotent.
But I am sure for this price Hikma, Btg or sny similar small cap company will buy revenues of Vectura and increased capitalization will help buyer to enter FTSE 100.

[pooroldboy55] 09/2/2018 11:44

Ok here's one to cheer us up just be glad your not in(i hope) Hikma only worth a third of 12 months ago £25 down to £8,54p.

[fhmktg] 09/2/2018 11:17

Q1 is scheduled for an up date so not too long to wait!

[polaris] 09/2/2018 10:05

No, its 15% of net US sales. VEC will be involved in the supply and manufacturing chain as well as a royalty %age. Better to say that it is 15% of net sales as revenues not royalties. Margin on that 15% is more likely to be 5-6% of net US sales of the generic. Remember it is only US sales and that currently accounts for 50% of net Advair/seretide global sales.

Also, one of the articles yesterday postulated that Hikma will not be in a position for approval until 2020. Mylan are still confident of resolution this year, though personally i do not share their optimism. We need more information from Sandoz/Novartis on the content of the CRL and the potential impact on generic entry date.

The only company this is really good for is GSK, as it protects their current Advair market while they switch patients to other treatments. By the time that generics come to market in the US then the market size may be 'only' 1Bn GBP (cf. 1.6 Bn 2017 market size). The generics will immediately cause significant price pressure and that market falls by more than 50% in value for the same volume of sales. Top generic will get 30-35% of those sales and, assuming it is Hikma, VEC will get 15% revenues on total US sales (30%x500Mx15%) to the tune of about 22.5M GBP. Margin on that will be, at best, 10M GBP. Generic Advair will not be such a big thing for VEC and the longer the incumbant has protection the more likely patients will be switched to something that has no generic alternative.

The impact of a resolution in favour of VEC v GSK in the IP court battle on the Ellipta series of products is of more value to VEC.

regards,

Paul

[chop55] 09/2/2018 08:57

The Novartis news from yesterday, that they also received a CRL from the FDA and will delay their ADVAIR generic, is very positive for VEC. VEC/Hikma is in my opinion now in the lead position for an Advair generic for the US market. We know that the Mylan product has substantial problems and even if Hikma has to perform one more study Hikma/VEC will probably be the first with a generic on the market.
Hope that some investors will also see this, before one of the big players will make a takeover offer for VEC to participate on the 15% royalties for that product.
I'll buy now......

[pooroldboy55] 09/2/2018 08:29

Well if we drop though the 70s as quick as we did the 80s may 66p forcast looks well on .

[pooroldboy55] 08/2/2018 16:40

Proof if proof was needed this is being worked, 4p during the day but ends up where it started buy back what a waste of money .And again ut close well below bid price.

[diesel] 08/2/2018 13:38

The buyback programme doesn't seem to mandated with buying maximum amount at minimum price, not sure if this will have proved to be worthwhile. Seems to have flagged to the market a management with little better to invest their cash pile.

[diesel] 08/2/2018 13:38

The buyback programme doesn't seem to mandated with buying maximum amount at minimum price, not sure if this will have proved to be worthwhile. Seems to have flagged to the market a management with little better to invest their cash pile.